Saturday, March 17, 2018

Medicare will cover genetic tests for cancer patients

CANCER DIGEST – Mar. 17, 2018 – The Centers for Medicare & Medicaid Services (CMS) announced on Mar. 16 that Medicare will cover genetic testing needed to match cancer patients with targeted immunotherapies. Specifically Medicare will cover Next Generation Sequencing (NGS) for patients with advanced cancer that has spread or has relapsed or fails to respond to other therapies.

Saturday, March 10, 2018

UK’s National Health Service to trial mpMRI for prostate cancer

Patient being positioned for an MRI – image used under
Creative Commons share alike license from Wikipedia
CANCER DIGEST – March 10, 2018 –In an effort to improve and speed up prostate cancer diagnosis, Britain’s National Health Service has launched a trial of a "one-stop" service in three west London hospitals. The goal is to complete all the tests needed to tell a man whether or not he has prostate cancer in one day.

Saturday, February 24, 2018

Trojan Horse targets metastatic cancer

Image credit: Pellecchia Lab, UC Riverside
CANCER DIGEST – Feb. 24, 2018 – Researchers have developed a Trojan Horse that delivers anti-cancer drug to a metastatic cancer cell. If proven successful, it could be used to reduce or halt metastases, which is the leading cause of death in cancer.

Once cancer metastasizes, or spreads to other parts of the body, there is no current therapy that can target those traveling cancer cells, and chemotherapy is indiscriminate, destroying healthy as well as cancerous cells.

Saturday, February 17, 2018

Accuracy of tests for predicting breast cancer recurrence vary significantly

Image courtesy Queen Mary
University of London
CANCER DIGEST – Feb. 17, 2018 – Tests used to predict breast cancer recurrence vary significantly in accuracy according to the first side-by-side comparison of the four most common tests.

In a study published in the Feb. 15, 2018 journal JAMA Oncology researchers led by Ivana Sestak, PhD of the Centre for Cancer Prevention at Queen Mary University of London, compared the predictive performance of the four most widely used biomarker analysis tests: Oncotype DX, PAM50, Breast Cancer Index (BCI) and the EndoPredict (EPclin), which all work by looking at the levels of multiple genes related to breast cancer.

Saturday, February 10, 2018

Imaging-first strategy effective for prostate cancer

CANCER DIGEST – Feb. 9, 2018 – An advanced imaging technique is a cost-effective first test for the diagnosis of prostate cancer when followed by a combination imaging-guided biopsy say researchers.

The PROMIS study published in the January 2018 European Urology was designed to compare cost and effectiveness of three diagnostic strategies: transrectal ultrasound-guided biopsy (TRUSB), template prostate mapping biopsy (TPMB), and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer.